Pediatric allergy and respiratory disease (소아알레르기 및 호흡기학회지)

The Korean Academy of Pediatric Allergy and Respiratory Diseasse (대한소아알레르기호흡기학회)
권호 표지

천식에서 IL-4/IL-13 사이토카인 및 수용체

Yang, Eun-Seok
양은석

  • Published : 20050000
⟨ Previous Next ⟩

Abstract

Asthma is a chronic allergic inflammatory disease of lung. The initiation and progression of asthma is dependent on the cytokines interleukin(IL)-4 and IL-13 acting through related receptor complexes. Disease pathogenesis is effected by intracellular signaling pathways that couple primarily to specific motifs within the intracellular domain of the IL-4 receptor α chain(IL-4Rα), a subunit that is common to the IL-4 and IL-13 receptor complexes. Neutralizing anti-cytokine strategies have proven to be highly successful on dissecting relevant effector pathways in experimental allergic disease, and are now entering clinical trials in human allergic disorders. Although there have been only a few clinical studies on the effects of cytokine modulators in asthma, this line of research and development appears promising. [Pediatr Allergy Respir Dis(Korea) 2005;15:1-11]

Keywords

References

  1. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001;344:350-62 https://doi.org/10.1056/NEJM200102013440507
  2. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway remideling in asthma : new insights. J Allergy Clin Immunol2003;111:215-25 https://doi.org/10.1067/mai.2003.128
  3. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remideling in asthma. J Clin Invest 1999;104:1001-6 https://doi.org/10.1172/JCI8124
  4. Nelms K, Keegan AD, Zamorano J. Ryan JJ, Paul WE. The IL-4 receptor : signaling mechanisms and biologic functions. Annu Rev Immunol 1999;17:701-38 https://doi.org/10.1146/annurev.immunol.17.1.701
  5. Hoffjan S, Ober e. Present status in the genetic studies of asthma. Curr Opin Immunol 2002;14:709-17 https://doi.org/10.1016/S0952-7915(02)00393-X
  6. Marsh DG, Neely JD, Breazcale DR, Ghosh B, Friedhoff LR, Ehrlich-Kautzky E, et al. Linkage analysis of IL-4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 1994;264: 1152-6 https://doi.org/10.1126/science.8178175
  7. Bharadwaj A, Agrawal DK. Immunomodulation in asthma: a distant dream or a close reality? Int Immunophamacol 2004;4:495-511
  8. Cohn L, Ray A. T - helper type 2 cell-directed therapy for asthma. pharmacol Ther 2000;88:187-96 https://doi.org/10.1016/S0163-7258(00)00091-7
  9. Dabbagh K, Takeyama K, Lee HM, Ueki IF, Lausier JA, Nadel JA. IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J Immuol 1999;162:6233-7
  10. Kips JC, Tournoy, Pauwels. New anti-asthma therapies: suppression of the effect of interleukin(IL)-4 and IL-5. Eur Respir J 2001;17:499-506 https://doi.org/10.1183/09031936.01.17304990
  11. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, jasmin C, Canonica GW, Azzarone B. IL4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 1998;10:1421-33 https://doi.org/10.1093/intimm/10.10.1421
  12. Moser R, Fehr J. Bruijnzeel PL. IL-4 controls the selective endothelium-drive transmigration of eosinophils from allergic individuals. J Immunol 1992;149:1432-S
  13. Vella A, Teague TK, Ihle J, Kappler J, Marrack P. Interleukin 4(IL-4) or IL-7 prevents death of resting T cells: Stat-6 is probably not required for the effect of IL-4. Exp Med 1997;186:325-30 https://doi.org/10.1084/jem.186.2.325
  14. Kips JC Cytokines in asthma. Eur Respir J 2001;18(suppl):24s-33s https://doi.org/10.1183/09031936.01.00229601
  15. Minty Z, Chalon P, Derocq ]M, Dumont X, Guillemot JC, Kaghad M, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993;362:248-50 https://doi.org/10.1038/362248a0
  16. de Vries JE. Molecular and biological characteristics of interleukin-13. Chem Immunol 1996;63:204-18 https://doi.org/10.1159/000319487
  17. Brown KD, Zurawski SM, Mosmann TR, Zurawski G. A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 1989;142:67987
  18. Smirnov DV, Smirnova MG, Korobko VG, Frolova El. Tandem arrangement of human genes for interleukin-Id : resemblance in their organization. Gene 1995;155:277-81 https://doi.org/10.1016/0378-1119(94)00720-D
  19. Octtgen HC, Geha RS. IgE regulation and roles in asthma pathogenesis, J Allergy Clin Immunol 2001;107:429-40 https://doi.org/10.1067/mai.2001.113759
  20. Zurawski G, de Vries ]E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994;15:19-26 https://doi.org/10.1016/0167-5699(94)90021-3
  21. Horie S, Okubo Y, Hossain M, Sato E, Nomura H, Koyama S, et al. Interleukin-13 but not interleukin-d prolongs eosinophil survival and induces eosinophil chemotaxis, Intern Med 1997;36:179-85 https://doi.org/10.2169/internalmedicine.36.179
  22. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et a1. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physi ologic abnormalities, and eotaxin production. J Clin Invest 1999;103:779-88 https://doi.org/10.1172/JCI5909
  23. Chatila TA. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol Med 2004:10:493-9 https://doi.org/10.1016/j.molmed.2004.08.004
  24. Leonard WJ, Lin JX. Cytokine receptor signaling pathways, J Allergy Clin Immunol 2000:105:877-88 https://doi.org/10.1067/mai.2000.106899
  25. de Vries JE. The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 1998:102:165-9 https://doi.org/10.1016/S0091-6749(98)70080-6
  26. Andrews R, Rosa L, Daines M, Khurana Hershcy G. Reconstitution of a functional human type II IL-4/lL-13 receptor in mouse B cells: demonstration of species specificity. J Immunol 2001;166:1716-22 https://doi.org/10.4049/jimmunol.166.3.1716
  27. Gurjit K, Khurana Hershey. IL-13 receptors and signaling pathways: An evolving web. J Allergy Clin Immunol 2003:111:677-90 https://doi.org/10.1067/mai.2003.90
  28. Yang G, Yolk A, Petley T, Emmell E, GilesKomar J, Shang X, et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness inflammation and airway remodeling. Cytokine 2004;28:224-32 https://doi.org/10.1016/j.cyto.2004.08.007
  29. Pernis AB, Rothman PB. JAK-STAT signaling in asthma. J Clin. Invest 2002;109:1279-83 https://doi.org/10.1172/JCI0215786
  30. Kawakami K, Taguchi J, Murata T, Puri RK. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001;97:2673-9 https://doi.org/10.1182/blood.V97.9.2673
  31. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JE, Agosti ]M, et a1. Interleukin-d receptor in moderate atopic asthma. A phase l/lI randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160:1816-23 https://doi.org/10.1164/ajrccm.160.6.9808146
  32. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, et a1. Efficacy of soulble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107:963-70 https://doi.org/10.1067/mai.2001.115624
  33. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, et al. Interleukin-13 : central mediator of allergic asthma. Science 1998;282:2258-61 https://doi.org/10.1126/science.282.5397.2258
  34. Grunig G, Wamock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, et a1. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261-3 https://doi.org/10.1126/science.282.5397.2261
  35. Daines MO, Hershey GK. A novel mechanism by which interferon-gamma can regulate interleukinill.) 13 responses. Evidence for intra-cellular stores of IL-13 receptor alpha-Z and their rapid mobilization by interferongamma. J Biol Chem 2002;277:10387-93 https://doi.org/10.1074/jbc.M108109200
  36. Oshima Y, Puri RK. Characterization of a powerful high affinity antagonist that inhibit biological activities of human interleukin-13 J Biol Chem 2001;276:15185-91 https://doi.org/10.1074/jbc.M010159200
  37. Kioi M, Kawakami K, Puri RK. Mechanism of action of interleukin-13 antagonist(IL13E13K) in cells expressing various types of IL-4R. Cell Immunol 2004;229:41-51 https://doi.org/10.1016/j.cellimm.2004.06.005
  38. Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995;270:8797-804 https://doi.org/10.1074/jbc.270.15.8797
  39. Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP, et al. Targeting of interleukin-13 receptor on human renal carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996;87:4333-9
  40. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999;189: 1939-46 https://doi.org/10.1084/jem.189.12.1939